OP0060 CLINICAL CONSEQUENCES OF INFLIXIMAB IMMUNOGENICITY AND THE IMPACT OF THERAPEUTIC DRUG MONITORING: SECONDARY ANALYSES OF A RANDOMISED CLINICAL TRIAL

Authors: Brun, M.K. ^{1, 2}, Bjørlykke, K.H. ^{2, 3}, Gehin, J.E. ⁴, Warren, D.J. ⁴, Klaasen, R.A. ⁴, Sexton, J. ¹, Sandanger, Ø. ⁵, Kvien, T.K. ^{1, 2}, Mørk, C. ⁶, Jahnsen, J. ^{2, 3}, Bolstad, N. ⁴, Jørgensen, K.K. ³, Haavardsholm, E.A. ^{1, 2}, Goll, G.L. ¹, Syversen, S.W. ¹

Source: In Annals of the Rheumatic Diseases June 2023 82 Supplement 1:40-40

Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study.

Authors: Gehin, JE, Warren, DJ, Syversen, SW, Lie, E, Sexton, J, Loli, L, Wierød, A, Bjøro, T, Kvien, TK, Bolstad, N, Goll, GL

Source: Scandinavian Journal of Rheumatology; Nov 2021, Vol. 50 Issue 6, p445-454, 10p

Subject Terms: PSORIATIC arthritis, JOINT diseases, GOLIMUMAB, DRUG monitoring, TERMINATION of treatment, ANKYLOSING spondylitis

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

ADALIMUMAB SERUM DRUG LEVELS AND ANTIDRUG ANTIBODIES: ASSOCIATION TO DISEASE ACTIVITY AND DRUG SURVIVAL IN INFLAMMATORY ARTHRITIS PATIENTS.

Authors: Jyssum, I., Gehin, J. E., Kristianslund, E., Sexton, J., Worren, D., Hu, Y., Kvien, T. K., Haavardsholm, E. A., Bolstad, N., Syversen, S. W., Goll, G. L.

Source: Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p421-422, 2p

DIFFERENCES IN SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS TREATED WITH ORIGINATOR VS BIOSIMILAR ADALIMUMAB.

Authors: Jyssum, I., Gehin, J. E., Kristianslund, E., Sexton, J., Worren, D., Hu, Y., Kvien, T. K., Haavardsholm, E. A., Bolstad, N., Syversen, S. W., Goll, G. L.

Source: Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p362-363, 2p

This result is not displayed to guests.
Login for full access.

SUN-P100: Tomato Intake, Gleason Score, and Prostate Specific Antigen in Prostate Cancer Patients

Authors: Paur, I., Carlsen, M.H., Lilleby, W., Bolstad, N., Bjoro, T., Smeland, S., Karlsen, A.S., Blomhoff, R.

Source: In Clinical Nutrition September 2017 36 Supplement 1:S91-S91

Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories.

Authors: Bader, L. I., Solberg, S. M., Kaada, S. H., Bolstad, N., Warren, D. J., Gavasso, S., Gjesdal, C. G., Vedeler, C. A.

Source: Scandinavian Journal of Immunology; Sep2017, Vol. 86 Issue 3, p165-170, 6p

Subject Terms: INFLIXIMAB, DRUG design, TUMOR necrosis factors, ANTIBIOTICS, CLINICAL trials

CLINICAL CONSEQUENCES OF INFLIXIMAB IMMUNOGENICITY AND THE IMPACT OF THERAPEUTIC DRUG MONITORING: SECONDARY ANALYSES OF A RANDOMISED CLINICAL TRIAL.

Authors: Brun, M. K., Bjørlykke, K. H., Gehin, J. E., Warren, D. J., Klaasen, R. A., Sexton, J., Sandanger, Ø., Kvien, T. K., Mørk, C., Jahnsen, J., Bolstad, N., Jørgensen, K. K., Haavardsholm, E. A., Goll, G. L., Syversen, S. W.

Source: Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p40-40, 3/4p

This result is not displayed to guests.
Login for full access.

P561 Anti-TNFalpha drug level measurements in IBD patients

Authors: Rekvig, M., Gedde Dahl, M., Bratlie, J., Bolstad, N., Moum, B., Jahnsen, J., Lundin, K.E.A.

Source: In Journal of Crohn's and Colitis February 2014 8 Supplement 1:S301-S302

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.